Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.35 |
| ▸ | TNF | P01375 | 2/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 3/20 | 0.33 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18779254 | 1.00 | ACSS2 (0.40) | ACSS2LMNASMN1; SMN2KDM4ENOD2 | |
| SCHEMBL20111256 | 0.92 | ACSS2 (0.42) | ACSS2LMNASMN1; SMN2ADORA1RPS6KA2 | |
| SCHEMBL18779265 | 0.92 | ACSS2 (0.42) | ACSS2LMNASMN1; SMN2ADORA1RPS6KA2 | |
| SCHEMBL18791841 | 0.85 | LMNA (0.34) | ACSS2LMNASMN1; SMN2KDM4ENOD2 | |
| SCHEMBL18791842 | 0.84 | ACACB (0.34) | ACSS2KDM4ENOD2TNFNOD1 | |
| SCHEMBL20110990 | 0.84 | ACSS2 (0.34) | ACSS2LMNASMN1; SMN2KDM4ENOD2 | |
| SCHEMBL18779253 | 0.84 | ACSS2 (0.34) | ACSS2LMNASMN1; SMN2KDM4ENOD2 | |
| SCHEMBL18779245 | 0.83 | PTGES (0.33) | ACSS2LMNASMN1; SMN2KDM4ENOD2 | |
| SCHEMBL18779275 | 0.82 | ACACB (0.34) | KDM4ENOD2TNFNOD1PTGES | |
| SCHEMBL17586626 | 0.81 | ACSS2 (0.38) | ACSS2LMNASMN1; SMN2ADORA1RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2023-01-05 | — | — | US | disclosed |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KNOPP BIOSCIENCES LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200062714-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2020-02-27 | — | — | US | disclosed |
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2019-09-19 | — | — | US | disclosed |
| WO-2018081825-A1 | BENZOIMIDAZOL-1, 2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | ACSS2 2521/4885LMNA 1881/4885SMN1; SMN2 286/4885 |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | ACSS2 2521/4885LMNA 1881/4885SMN1; SMN2 286/4885 |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | ACSS2 2521/4885LMNA 1881/4885SMN1; SMN2 286/4885 |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | ACSS2 2521/4885LMNA 1881/4885SMN1; SMN2 286/4885 |
| US-20200062714-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | ACSS2 928/4885LMNA 1754/4885SMN1; SMN2 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.